drugset / Trial / NCT02236936

Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck

NCT02236936

RandomizedParallel-groupOpen-labelTreatment

Summary

Prevention of critical weight loss. In patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) weight loss is a relevant clinical problem during radiotherapy and might result in higher treatment related toxicity and discontinuation of a potential curative treatment. Thus the investigators want to evaluate the efficacy of overnight parenteral nutritional (PN) support in patients with SCCHN treated with curative radiotherapy (RTX) in combination with Cetuximab (E) or Cisplatin (P).

Timeline

Start
2017-02-03
Primary completion
2019-07-10
Completion
2019-07-10

Drugs

EvaluationDrugModalityDoseRoute
Background Cetuximab Monoclonal antibody 250 mg/m2
Background Cisplatin Other / unclassified 40 mg/m2
Background Cisplatin Other / unclassified 100 mg/m2